How will lenacapavir change the “HIV” prevention landscape?
Quick update tonight.
As we have seen, Gilead Sciences and the media have been heavily promoting lenacapavir for PrEP, citing their early clinical trial data that showed promising results. Lenacapavir was initially marketed as Sunlenca, and was originally developed to treat “heavily treatment experienced” patients who have failed to respond to other ARVs. Why would we then make the leap to prescribing this for prevention?
Uptake of Gilead's Yeztugo will be swift, analyst says after discussion with HIV doc
Regardless, lenacapavir—which will be marketed for PrEP with the absolutely awful name Yeztugo—is being fast tracked with the hope that this will end the “HIV” epidemic. Will this treatment finally provide “proof of concept” for the HIV AIDS story?
Doubtful, for a few reasons. First, it is likely that the majority of people who take lenacapavir for PrEP would be people that were already on oral PrEP. I don’t think a lot of new consumers are going to turn out because all the people that believe they benefit from PrEP have already been ideologically captured. The people that are not on PrEP are not suddenly going to want to start it, because they have reasons for avoiding this medication and “convenience” is not likely to change too many minds. Also, oral PrEP has long since been touted to be “>99% effective” at preventing “HIV”—so how can Lenacapavir be expected to improve upon that? The HIV zealots have no answer for this question.
Let me know what you think.
Time will tell whether the best new marketing tricks they can come up with will be effective. We already know they won't be safe!!
I wonder if they’re going to try and push this as a less toxic form of PrEP? And I also wonder how they claim to maintain this as biochemically active for such a long time? Are they somehow blocking the body’s detox pathways. If so that’s really bad.